Home > Business > PTI > Report

Ranbaxy gets FDA nod for Amoxicillin

December 08, 2003 18:37 IST

Ranbaxy Laboratories on Monday said it has received final approval from the United States Food and Drugs Administration to manufacture and market Amoxicillin and Clavulnate Potassium tablets, a generic version of GlaxoSmithkline's Augmentin.

The total market for all forms of Amoxicillin and Clavulnate Potassium is estimated at $31.4 million, a Ranbaxy statement said in New Delhi.

The drug is indicated in the treatment of infections caused by susceptible strains designated organisms in conditions such as lower respiratory tract infections, otitis media, sinussitis, skin and skin structure infections and urinary tract infections.

Commenting on the approval, Jim Meehan, vice president, sales and marketing, Ranbaxy, said: "Amoxicillin and Clavulnate Potassium chewable tablets will be made available nationwide through retail pharmacies, wholesalers and distributors as quickly as inventories can be reached."


Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor




Related Stories


Ranbaxy plans Hyderabad units



People Who Read This Also Read


Gold prices hit new high

Maruti models top quality chart

Oil fields: microbes to be used






© Copyright 2003 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.











Copyright © 2003 rediff.com India Limited. All Rights Reserved.